Recombinant Human CYGB, N-His

Title: Introduction to Recombinant Human CYGB

Recombinant human CYGB (Cytoglobin) is a protein that belongs to the globin family and is encoded by the CYGB gene. It is a heme-containing protein that is highly conserved among different species, including humans, mice, and zebrafish. CYGB is primarily expressed in tissues with high oxygen consumption, such as the heart, lungs, and skeletal muscles. In recent years, there has been a growing interest in studying the structure, activity, and potential applications of recombinant human CYGB.

Structure of Recombinant Human CYGB

The human CYGB protein consists of 190 amino acids and has a molecular weight of approximately 21 kDa. It contains a heme-binding pocket that is essential for its function. The structure of CYGB is similar to that of other globins, such as hemoglobin and myoglobin, with a globular fold and eight alpha-helices. However, CYGB has a unique heme pocket that is more exposed, allowing for easier access to oxygen.

Activity of Recombinant Human CYGB

The primary function of CYGB is to facilitate oxygen transport and storage in tissues with high metabolic demands. It has been shown to bind both oxygen and carbon monoxide, with a higher affinity for the latter. This binding of carbon monoxide to CYGB has been suggested to play a role in protecting cells from oxidative stress. Additionally, CYGB has been found to have antioxidant properties, helping to reduce the levels of reactive oxygen species in cells.

Recombinant human CYGB has also been shown to have a role in regulating cell growth and proliferation. Studies have demonstrated that CYGB can inhibit cell proliferation and promote cell death in cancer cells. This suggests that CYGB may have potential therapeutic applications in cancer treatment.

Application of Recombinant Human CYGB

The unique properties and functions of recombinant human CYGB make it a promising candidate for various applications in the fields of medicine and biotechnology. One potential application is in the treatment of diseases related to oxidative stress, such as cardiovascular diseases and neurodegenerative disorders. CYGB’s ability to bind carbon monoxide and reduce oxidative stress could be harnessed for therapeutic purposes.

Another potential application of recombinant human CYGB is in cancer treatment. As mentioned earlier, CYGB has been shown to inhibit cell proliferation and promote cell death in cancer cells. This makes it a potential target for cancer therapies, either as a standalone treatment or in combination with other therapies.

Moreover, recombinant human CYGB has also been studied for its potential use in tissue engineering. Its ability to promote cell death and regulate cell growth could be utilized in developing artificial tissues and organs.

Conclusion

In conclusion, recombinant human CYGB is a highly conserved protein with a unique structure and multiple functions. Its role in oxygen transport, antioxidant activity, and cell regulation make it a promising candidate for various applications in medicine and biotechnology. Further research and development of recombinant human CYGB could potentially lead to new and innovative treatments for various diseases and disorders.

ProteoGenix catalogue number ARO-P13219. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 23.71 kDa; Fragment: Met1-Pro190; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet